Latest News by Industry
MENLO PARK, Calif.--(BUSINESS WIRE)--Nov 21, 2022--
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 34 th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 1:30 p.m. Eastern Time in New York, NY.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform ® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and News Center and follow Personalis on LinkedIn and Twitter.
View source version on businesswire.com:https://www.businesswire.com/news/home/20221121005169/en/
CONTACT: Investor Relations Contact:
Caroline Corner
investors@personalis.com
415-202-5678Media Contact:
Jennifer Temple
pr@personalis.com
www.personalis.com
650-752-1300
KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL ONCOLOGY GENERAL HEALTH HEALTH HOSPITALS GENETICS CLINICAL TRIALS
SOURCE: Personalis, Inc.
Copyright Business Wire 2022.
PUB: 11/21/2022 04:01 PM/DISC: 11/21/2022 04:02 PM
http://www.businesswire.com/news/home/20221121005169/en